Groh, M. E., Maitra, B., Szekely, E. & Koc, O. N. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp. Hematol. 33, 928-934
Division of Hematology/Oncology, Department of Medicine, Case Comprehensive Cancer Center at Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH 44106, USA. Experimental Hematology
(Impact Factor: 2.48).
09/2005; 33(8):928-34. DOI: 10.1016/j.exphem.2005.05.002
Human bone marrow-derived mesenchymal cells (MSCs) are precursors of nonhematopoietic mesenchymal cells of the bone marrow microenvironment. MSCs were shown to inhibit alloreactive T lymphocytes, but the mechanism and mediators of this effect are not fully understood. Here we describe a novel interaction between blood monocytes and bone marrow-derived, culture-expanded MSCs, which results in inhibition of T-lymphocyte activation. We found that CD14+ monocytes from blood activate MSCs to secrete inhibitory molecules that lead to inhibition of alloreactive T cells. This cellular communication is not contact-dependent, but rather is mediated by soluble factors that include interleukin (IL)-1beta. MSC-mediated inhibition of alloreactive T lymphocytes is associated with downregulation of activation markers CD25, CD38, and CD69 detected both in CD4+ and CD8+ T lymphocytes. The cytokines secreted by MSCs that mediate T-cell inhibition include transforming growth factor-beta1, but not IL-10. The interaction between blood monocytes and the MSCs represents a unique immune regulatory paradigm that can potentially be exploited in clinic.
Available from: Felipe Saldanha-Araujo
- "In fact, it is well known that MSCs do not stimulate T-cell activation. Some studies have shown that MSCs cause a reduction in the expression of activation markers  , while others found no change in expression of these markers  . Taken together, the ability of MSCs to escape from immune response and to modulate T-cell proliferation renders them attractive candidates for use in cell therapy. "
[Show abstract] [Hide abstract]
ABSTRACT: Mesenchymal stromal cells (MSCs) are multipotent cells, which can give rise to several cell types including osteoblasts, adipocytes, and chondroblasts. These cells can be found in a variety of adult and fetal tissues, such as bone marrow, adipose tissue, cord blood, and placenta. In recent years, the biological properties of MSCs have attracted the attention of researchers worldwide due to their potential application for treating a series of clinical situations. Among these properties, special attention should be given to the immunoregulatory potential of those cells. MSCs are able to act on all cells of the immune system, which includes the capacity to inhibit the proliferation and function of T-cells. This feature renders them natural candidates to treat several diseases in which cellular immune response is exacerbated. In this review, we outline the main mechanisms by which MSCs immunosuppress T-cell response, focusing on cell-cell contact, secretion of soluble factors, and regulatory T-cell generation. The influence of surface markers in the immunosuppression process and features of MSCs isolated from different sources are also discussed. Finally, the influences of toll-like receptors and cytokines on the inflammatory microenvironment are highlighted regarding the activation of MSCs to exert their immunoregulatory function.
Available from: Andrea Wieck
- "The current body of evidence provides an outline of which specific molecules are involved in the immunomodulatory effects of MSCs on effector T lymphocyte proliferation and function. In the human immune system, the effects of MSCs on T cells are mediated primarily by independent cell–cell contact, evincing the importance of secretion of such factors as  IL-1β , TGFβ-1 , HGF , PGE2, IDO, heme oxygenase-1 (HO-1), leukemia inhibitory factor (LIF) , IGF , sHLA-G5 , galectin , and Jagged-1 . "
[Show abstract] [Hide abstract]
ABSTRACT: Mesenchymal stem cells (MSCs) are being widely studied as potential cell therapy agents due to their immunomodulatory properties, which have been established by in vitro studies and in several clinical trials. Within this context, mesenchymal stem cell therapy appears to hold substantial promise, particularly in the treatment of conditions involving autoimmune and inflammatory components. Nevertheless, many research findings are still contradictory, mostly due to difficulties in characterization of the effects of MSCs in vivo. The purpose of this review is to report the mechanisms underlying mesenchymal stem cell therapy for acute graft-versus-host disease, particularly with respect to immunomodulation, migration, and homing, as well as report clinical applications described in the literature.
Available from: Ashlee Watts
- "Finally, MSCs might also be anti-inflammatory through inhibition of IFN-γ and TNF-α and stimulation of metalloproteinase inhibitors and anti-inflammatory interleukins such as IL-10 (Caplan 2009). The most exciting element of the MSC is their apparent exquisite responsiveness to their micro-environment, in that they behave according to the environment in which they are placed (Groh et al. 2005; Prockop 2009). In this manner, MSCs would respond appropriately to the degree of disease and modulate the local environment in favour of reduced inflammation, reduced apoptosis and/or enhanced matrix synthesis by endogenous progenitors and tissue specific cells. "
[Show abstract] [Hide abstract]
ABSTRACT: Stem cell therapies for musculoskeletal disorders are becoming commonplace in the horse. In order to decipher the many options available for stem cell therapy and interpret results of accumulating experimental and clinical data, practitioners should have a basic understanding of stem cells.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.